|
Originally published In Press as doi:10.1074/jbc.M011317200 on June 8, 2001
J. Biol. Chem., Vol. 276, Issue 33, 31368-31375, August 17, 2001
Sequential Activation of Protein Kinase C (PKC)- and
PKC- Contributes to Sustained Raf/ERK1/2 Activation in Endothelial
Cells under Mechanical Strain*
Jing-Jy
Cheng,
Being-Sun
Wung,
Yuen-Jen
Chao, and
Danny Ling
Wang
From the Cardiovascular Division, Institute of Biomedical Sciences,
Academia Sinica, 11529 Taipei, Taiwan, Republic of China
Received for publication, December 15, 2000, and in revised form, May 8, 2001
 |
ABSTRACT |
Endothelial cells (ECs) are constantly subjected
to hemodynamic forces including cyclic pressure-induced strain. The
role of protein kinase C (PKC) in cyclic strain-treated ECs was
studied. PKC activities were induced as cyclic strain was initiated.
Cyclic strain to ECs caused activation of PKC- and - . The
translocation of PKC- and - but not PKC- from the cytosolic to
membrane fraction was observed. An early transient activation of
PKC- versus a late but sustained activation of
PKC- was shown after the onset of cyclic strain. Consistently, a
sequential association of PKC- and - with the signaling molecule
Raf-1 was shown. ECs treated with a PKC inhibitor (calphostin C)
abolished the cyclic strain-induced Raf-1 activation. ECs under cyclic
strain induced a sustained activation of extracellular signal-regulated
protein kinases (ERK1/2), which was inhibited by treating ECs with
calphostin C. ECs treated with a specific
Ca2+-dependent PKC inhibitor (Go 6976) showed
an inhibition in the early phase of ERK1/2 activation but not in the
late and sustained phase. ECs transfected with the antisense to
PKC- , the antisense to PKC- , or the inhibition peptide to PKC-
reduced strain-induced ERK1/2 phosphorylation in a temporal manner.
PKC- mediated mainly the early ERK1/2 activation, whereas PKC-
was involved in the sustained ERK1/2 activation. Strained ECs increased
transcriptional activity of Elk1 (an ERK1/2 substrate). ECs transfected
with the antisense to each PKC isoform reduced Elk1 and monocyte
chemotactic protein-1 promotor activity. Our findings conclude that a
sequential activation of PKC isoform ( and ) contribute to
Raf/ERK1/2 activation, and PKC- appears to play a key role in
endothelial adaptation to hemodynamic environment.
 |
INTRODUCTION |
Vascular endothelial cells
(ECs)1 are constantly under
the influence of hemodynamic forces including flow-induced shear stress and pressure-generated cyclic strain. These hemodynamic forces play an
essential role in maintaining vascular integrity by inducing the
release of vasoactive substances and modulating gene expression (1, 2).
Studies have examined how intracellular signals are involved in
transmitting mechanical forces into second messengers and subsequently
gene expression (3, 4). Shear flow stimulates the signals involved in
the ERK1/2 and JNK pathways. These signals may result in the induction
of various genes' expression including platelet-derived growth factor
(5), Egr-1 (6), c-fos (7), monocyte chemotactic protein-1
(MCP-1) (8), and intercellular adhesion molecule-1 (ICAM-1) (9).
Because rhythmic distension of the vessel wall is a component of
pulsatile flow, cyclic strain on vessel walls plays an important role
in modulating gene expression. Earlier studies from our laboratory
showed that ECs under cyclic strain increase their expression of MCP-1
(10-12), ICAM-1 (13, 14), and early growth response-1 (Egr-1) (15).
Signaling pathways involving ERK1/2 and c-Jun N-terminal kinase
participate in mechanical force-induced gene expression (3, 12, 16).
However, the initial events and the following networks of signaling
pathways are still poorly understood.
Cyclic strain to ECs activates intracellular second messengers.
Activation of protein kinase C (PKC) is associated with an increase of
phosphatidyl inositol turnover and intracellular calcium (17). PKC is
activated by diacylglycerol (DAG), which is derived either from
phosphatidylinositide (PI) or phosphatidylcholine (PC). PKC isoforms in
human ECs have been identified that cover PKC- , PKC- , PKC- ,
and PKC- (18). PKC- belongs to a
Ca2+-dependent group, and the isoforms PKC-
and PKC- belong to a Ca2+-independent group. Studies
have indicated that PKC is involved in shear stress- and cyclic
strain-induced gene expression of platelet-derived growth factor and
Et-1 in ECs (19, 20). Indeed, PKC- is required for fluid shear
stress-mediated activation of ERK1/2 in ECs (21). In smooth muscle
cells, stretching promotes DNA synthesis via activation of PKC (22).
Our previous studies demonstrated that cyclic strain to ECs increases
gene expression of MCP-1, which is regulated by PKC (10). Further
studies indicated that cyclic strain induces the Ras/Raf-1/ERK1/2
signaling pathway and results in an increase of gene expression of
MCP-1 and Egr-1 (11, 15). The upstream signaling pathway and/or
signaling network that lead to activation of Ras/Raf-1/ERK1/2 by cyclic strain remain unclear. Among the likely signaling networks, different PKC isoforms have been shown to modulate the ERK1/2 signaling pathway
under different stimuli (23, 24). However, direct evidence of any of
the PKC isoforms being involved in the signaling pathway during
endothelial response to cyclic strain has not been clearly defined. In
the present study, we demonstrate that ECs subjected to cyclic strain
increase PKC activities and that PKC- and PKC- are sequentially
activated for Raf/ERK1/2 activation. PKC- and PKC- contribute to
the early and late phase of ERK1/2 activation, respectively, in cyclic
strain-treated ECs. The consequence of these PKCs being activated by
cyclic strain leads to cellular adaptation including gene
induction in ECs. Our results provide direct evidence of PKC isoforms'
participation in signaling transduction in ECs under a hemodynamic environment.
 |
MATERIALS AND METHODS |
In Vitro Cyclical Strain on ECs--
The strain unit Flexcell
FX-2000 (Flexcell, McKeesport, PA) consisted of a vacuum unit linked to
a valve controlled by a computer program (25). Bovine aortic ECs
cultured on a flexible membrane base were deformed by a sinusoidal
negative pressure that produced an average strain of 12% at a
frequency of 1 Hz.
PKC Activity Assay--
ECs were scraped in ice-cold lysis
buffer (20 mM Tris-HCl, pH 7.4, 10 mM EDTA, 5 mM EGTA, 10 mM benzamidine, 50 µg/ml
phenylmethylsulfonyl fluoride, 0.05% leupeptin) and sonicated. Total
cell lysate was collected, and PKC activity was detected based on an
enzyme-linked immunosorbent assay that utilizes a synthetic peptide and
a monoclonal antibody that recognizes the phosphorylated form of the
peptide (Upstate Biotechnology, Inc., Lake Placid, NY).
Separation of PKC and Immunoblot Analysis--
ECs were scraped
into lysis buffer containing 2-mercaptoethanol and protease inhibitors.
After sonication and centrifugation, the supernatants and pellets were
collected as cytosolic and membrane fractions. For experiments to
detect the phosphorylation in PKC, total cell lysate was used. Proteins
were extracted in buffer containing SDS and subjected to SDS-PAGE. The
PKC isoforms were analyzed with PKC monoclonal antibodies (Transduction
Laboratories). To detect serine phosphorylation in PKC, antibody to
phospho-PKC- (Ser657) or phospho-PKC-
(Ser719) (Transduction Laboratories) was used.
Antigen-antibody complexes were detected using horseradish
peroxide-labeled rabbit anti-mouse IgG and an ECL detection system
(Amersham Pharmacia Biotech). For detection of phosphorylated ERK1/2
(pERK1/2), pERK1/2 antibody (Transduction Laboratories) was used. For
the Raf activation detection, antibody specific to the phosphorylated
activation site (Ser402; Transduction Laboratories) of Raf
was used. Antibody conjugated with alkaline phosphatase was used as
second antibody, and results were obtained using a chemiluminescent
detection kit (Tropix Inc.).
DNA Plasmids, Transfection, and Luciferase Assays--
An Elk1
transduction pathway-reporting system was obtained from Stratagene (La
Jolla, CA) that contains plasmids GAL/Elk1-(307-428) and GAL4-Luc. An
MCP-1 promoter construct ( 540 base pairs) containing the
luciferase reporter gene (26) was also used. Transfection was performed
using the LipofectAMINE method (Life Technologies, Inc.), and the
pSV- -galactosidase plasmid was cotransfected to normalize the
transfection efficiency. Phosphorothioate oligonucleotides corresponding to bovine PKC- or PKC- were synthesized by
PerkinElmer Life Sciences. The sequences of sense, scramble, and
antisense to PKC- were 5'-GTCCCTCGCCGCCTCCTG-3',
5'-GGTTTTACCATCGGTTCTGG-3', and 5'-GTCCTCGCCGCTCCCCTG-3', respectively.
The sequences of scramble and antisense to PKC- were
5'-TACGCATAACGCGCTGGTGG-3' and 5'-ATTGAACACTACCAT-3', respectively. The sequence of the PKC- inhibitory peptide was Glu-Ala-Val-Ser-Leu-Lys-Pro-Thr. These oligonucleotides and the inhibitory peptide, characterized as described (21, 27-29), were transfected into ECs using the LipofectAMINE method.
Immunoprecipitation of Raf-1--
ECs were lysed with buffer
containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, and
a protease inhibitor mixture. Cells were disrupted by repeated
aspiration through a 21-gauge needle. After removing cellular debris,
the same amount of protein from each sample was incubated with
anti-Raf-1 monoclonal antibody (Transduction Laboratories). The immune
complex was then incubated with protein A/G-agarose for 1 h. The
immune complex was washed three times and resuspended in the sample buffer.
Immune Complex MAPK (ERK) Assay--
ECs were lysed and
immunoprecipitated with anti-ERK1/2 antibody (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA). The MAPK activity in the immune complex was
analyzed in reaction buffer (10 mmol/liter MgCl2, 1 mmol/liter dithiothreitol, 1 mmol/liter benzamidine, 25 mmol/liter
HEPES, 50 µmol/liter ATP, and 1 µCi of [ -32P]ATP)
containing myelin basic protein. The reaction was terminated with
sample buffer containing SDS. The samples were electrophoresed, and the
gel was imaged by autoradiography.
Statistical Analysis--
Statistical analyses were performed
using Student's t test. Data are expressed as mean ± S.E. Statistical significance was defined as p < 0.05.
 |
RESULTS |
Cyclic Strain Induces PKC Activity and Transmigration of PKC-
and - in ECs--
Our previous studies demonstrated that PKC is
involved in cyclic strain-induced gene expression of Et-1 and MCP-1 in
ECs (10, 30). To further elucidate the role of PKC in cyclic
strain-induced endothelial responses, PKC activity and PKC isoforms in
strained ECs were investigated. ECs under cyclic strain rapidly
increased their PKC activities. These increased PKC activities remained at elevated levels as the cyclic strain continued up to 6 h (Fig. 1A). PKC activation requires
phosphorylation of active sites. To demonstrate that PKCs were
activated after cyclic strain, serine phosphorylation of PKC-
(Ser657) and PKC- (Ser719) as an indication
of PKC activation was evaluated. As shown in Fig. 1B, ECs
under cyclic strain rapidly induced phosphorylation of
Ser657 on PKC- and maintained that at an activated form
for up to 3 h. In contrast, the phosphorylation of
Ser719 on PKC- showed apparent activation after 1 h
of strain treatment and maintained that up to 6 h.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 1.
Cyclic strain induces protein kinase C
activity. A, ECs were exposed to 12% strain for
various time intervals. Total PKC activities of cell homogenates were
measured by a nonradioactive assay as described under "Materials and
Methods." Results are expressed as mean ± S.E. from five
experiments. *, p < 0.05 versus static
control ECs. B, ECs subjected to cyclic strain for various
time intervals were collected. Total cell lysate was subjected to
SDS-PAGE and immunoblotted with phospho-PKC- (Ser657),
phospho-PKC- (Ser719), or PKC- antibody. Antibody to
PKC- was used to indicate that an equal amount of protein was
applied on each gel lane. Results are representative of three separate
experiments with similar results.
|
|
Immediately following lysis of ECs after strain treatment, the
cytosolic and membrane fractions were separated. Different PKC isoforms
from each fraction were analyzed. Three major PKC isoforms
(i.e. PKC- , - , and - ) were identified with
respective antibodies. ECs, after cyclic strain for 5 min, rapidly
induced their PKC- activity as shown by the strong PKC- migration
from the cytosolic to the membrane fraction (Fig.
2). These PKC- then gradually
retreated to the cytosolic fraction. The majority of PKC- returned
to the cytosolic fraction at 6 h after continuous cyclic strain.
Interestingly, the PKC- transmigration was not detected at the early
phase but instead became apparent at 1 h, reached maximal
activation at 3 h, and remained in an activated form even at
6 h after cyclic strain treatment (Fig. 2). In contrast to the
transmigration of PKC- and PKC- from the cytosolic to the
membrane fraction, the PKC- isoform was not activated and remained
in the cytosolic fraction during the entire 6-h cyclic strain
treatment. These observations are consistent with the sequential pattern of serine phosphorylation on active sites of PKCs shown in Fig.
1B. Our results clearly demonstrate a sequential
transmigration of PKC- and PKC- to the membrane fraction in ECs
after the onset of cyclic strain.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 2.
Sequential transmigration of
PKC- and PKC- to
membrane in cyclic strain-treated ECs. ECs subjected to cyclic
strain for various time intervals were collected and separated into
cytosolic (c) and membrane fractions (m). Equal
amounts of total proteins from each cell sample were subjected to
SDS-PAGE. PKC- , PKC- , and PKC- isoforms were identified with
respective monoclonal antibodies by Western blot. Results (mean ± S.E.) shown are from three separate experiments of respective PKC-
and PKC- . *, p < 0.05 versus cytosolic fraction in
controls. #, p < 0.05 versus membrane
fraction in controls.
|
|
Sequential Association of PKC- and PKC- with Raf-1 in Cyclic
Strain-treated ECs--
The direct phosphorylation of Raf-1 by PKC
isoforms has been suggested as an activation mechanism of PKC on the
Raf-1/ERK1/2 signaling pathway (31, 32). We previously demonstrated
that cyclic strain activates the Ras/Raf-1/ERK1/2 pathway (14). To demonstrate that PKC is involved in Raf-1 activation, ECs were pretreated with a PKC inhibitor, calphostin C, followed with cyclic strain treatment. As shown in Fig.
3A, the cyclic strain, while inducing an increased phosphorylation of Raf-1 in its activation site,
was significantly blunted by treating ECs with calphostin C. To further
elucidate the role of PKC isoforms in the Raf-1/ERK1/2 signaling
cascade, the association of each PKC isoform with Raf-1 in strained ECs
was assessed by immunoprecipitating Raf-1 with monoclonal antibodies
from total cellular extracts of ECs and by immunoblotting with
antibodies to PKC- or PKC- . Although an equal amount of Raf-1 was
shown in the immune complex, PKC isoform association with Raf-1
occurred in a temporal manner (Fig. 3B). In ECs under static
conditions, some PKC- was associated with Raf-1, but PKC- was
not. However, ECs subjected to cyclic strain for 5 min resulted in a
rapidly increased association of PKC- with Raf-1. This association
of PKC- with Raf-1 receded after 3 h of cyclic strain. In
contrast, PKC- was strongly associated with Raf-1 at this time
point. These findings of Raf-1 phosphorylation via PKC and sequential
association of PKC isoforms with Raf-1 are consistent with the finding
of temporal transmigration of PKC- and PKC- in ECs after cyclic
strain treatment.

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 3.
PKC is involved in Raf activation and
sequential association of PKC- and
PKC- with Raf in cyclic strain-treated
ECs. ECs, after cyclic strain treatment for 5 min (S5')
or 3 h (S3h), were lysed with buffer containing
protease inhibitors. A, ECs were pretreated with calphostin
C (Cal. C; 50 µmol/liter for 30 min) followed by cyclic
strain treatment. The same amount of protein was separated by 10%
SDS-PAGE and then subjected to Western blotting using Raf antibody
specific to the phosphorylated activation site. Results are
representative of three separate experiments with similar results.
B, after removing cellular debris, the same amount of
protein was incubated with anti-Raf monoclonal antibody. The immune
complexes were then incubated with protein A/G-agarose for 1 h.
The immune complexes were washed and suspended in sample buffer.
Proteins were separated by 10% SDS-PAGE and transferred onto
nitrocellulose membranes. Protein kinase C isoform was identified by
its respective antibody. Antibody against Raf was used to confirm that
an equal amount of Raf in immune complexes was applied to the gel.
Results are representative of three separate experiments with similar
results.
|
|
Sequential Activation of PKC- and - Contributes to
Strain-induced ERK1/2 Activation--
We previously demonstrated that
cyclic strain to ECs induces Egr-1 gene expression, which is
predominantly mediated via the Ras/Raf-1/ERK1/2 signaling pathway (15).
To further confirm that the ERK1/2 signaling pathway is involved, ECs
after cyclic strain for various intervals were lysed, and
phosphorylated ERK1/2 was analyzed with Western blotting using
anti-phosphorylated ERK1/2 antibody. Cyclic strain to ECs, similar to
those ECs after phorbol ester treatment, rapidly induced ERK1/2
activity (Fig. 4A). This ERK1/2 activity remained in a phosphorylated form as cyclic strain continued. Early and late activation of ERK1/2, corresponding to ECs at
5-min and 3-h treatment of the cyclic strain, were inhibited after
treating ECs with calphostin C (Fig. 4B). Consistently, cyclic strain-induced ERK1/2 kinase activity, as analyzed by
32P phosphorylation of myelin basic protein, was inhibited
in ECs pretreated with calphostin C (Fig. 4C). In contrast
to the activation of PKC- , PKC- activation is
Ca2+-dependent. To differentiate which PKC
isoforms contribute to the early phase versus the late but
sustained phase of ERK1/2 activity, ECs were pretreated with a specific
Ca2+-dependent PKC inhibitor, Go 6976, and then
subjected to cyclic strain. As shown in Fig. 4D, the early
phase of cyclic strain-induced ERK1/2 activity was significantly
inhibited after Go 6976 treatment of ECs. In contrast, strain-induced
ERK1/2 activity in the late but sustained phase was not affected by
this inhibitor treatment. These results support that a
sequential activation of PKC- and PKC- is involved in cyclic
strain-induced ERK1/2 activation in ECs.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
Cyclic strain induces tyrosine
phosphorylation of ERK1/2 and ERK1/2 kinase activity. ECs were
subjected to cyclic strain and then harvested. The cell lysate
collected was applied to SDS-PAGE followed by Western blot using
anti-phosphorylated ERK1/2 antibody. A, time course study.
Results (mean ± S.E.) are representative of three separate
experiments. *, phorbol ester (PMA; 0.5 µg/ml)-treated ECs
were used as positive controls. p < 0.05 versus pERK2 of control. #, p < 0.05 versus pERK1 of control. B, ECs pretreated with a
PKC inhibitor, calphostin C (Cal), for 0.5 h and
subjected to cyclic strain for 5 min (S5') or 3 h
(S3h). Phorbol ester-treated ECs were used as positive
controls. C, cyclic strain induces ERK1/2 activity. ECs
pretreated with calphostin C (Cal) for 0.5 h and then
subjected to cyclic strain for 5 min (S5') or 3 h
(S3h). ECs were lysed and immunoprecipitated with anti-MAPK
followed with protein A/G-agarose. The immune complex was analyzed for
its kinase activity using [ -32P]ATP and MBP.
D, ECs were treated with a specific
Ca2+-dependent PKC inhibitor, Go 6976 (Go), followed by cyclic strain for 5 min (S5')
or 3 h (S3h). The cell lysate was subjected to Western
blot analysis. Results are representative of three separate
experiments.
|
|
Antisense Oligonucleotides to PKC- or - Inhibit Cyclic
Strain-induced ERK1/2 Activity--
To further confirm the role of
each PKC isoform in strain-induced ERK1/2 activity, ECs were pretreated
with antisense to PKC- or PKC- . ECs transfected with an antisense
(2 µmol/liter) to a particular PKC isoform significantly reduced the
protein expression of that PKC isoform in ECs (Fig.
5, A-D). Consistently,
antisense to PKC- and PKC- significantly inhibited PKC activity
in ECs after cyclic strain for 5 min and 3 h, respectively (Fig.
5E). When ECs were subjected to cyclic strain for 5 min,
only those ECs transfected with antisense to PKC- showed an
inhibition of ERK1/2 phosphorylation (Fig.
6A). In contrast, ECs
transfected with the scramble oligonucleotides did not affect ERK1/2
activity. This indicates that PKC- is required for early ERK1/2
activity. However, PKC- did not play a significant role at the late
phase of ERK1/2 activation, since antisense PKC- -transfected ECs did not inhibit ERK1/2 phosphorylation at 3 h after cyclic strain treatment (Fig. 6B). In contrast, ECs transfected with an
antisense to PKC- abolished the strain-induced ERK1/2 activity at
this later phase. PKC- involved in late phase of ERK1/2 was further confirmed by the inhibition of ERK1/2 activity in strained ECs transfected with the inhibitory peptide to PKC- (Fig.
6B). All of these data demonstrate that PKC- is required
for the early phase, while PKC- contributes mainly to the late and
sustained phase of cyclic strain-induced ERK1/2 activation in ECs.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 5.
Antisense oligonucleotides to
PKC- or PKC-
decrease the PKC isoform expression in ECs. ECs were either
transfected with a scramble oligonucleotide (Sc) or an
increasing concentration of antisense to PKC- (A) or
PKC- (C) for 6 h. Two days after transfection, ECs
were lysed, and the same amount of protein was subjected to Western
analysis using respective anti-PKC- , -PKC- , or -PKC- antibody.
The specificity of each antisense to PKC isoform was shown in
B and D. Results (mean ± S.E.) are
representative of three separate experiments with similar results. *,
p < 0.05 versus PKC- or PKC- in controls.
PKC- has no change in its protein expression and is shown
as an internal control. E, ECs were transfected with
antisense to PKC- and PKC- and subjected to mechanical strain.
The total PKC activities were accessed as described under "Materials
and Methods." Data are shown as relative activity (mean ± S.E.). *, p < 0.05 versus strained ECs which have been
transfected with corresponding scramble oligonucleotides.
|
|

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 6.
PKC- and
PKC- sequentially regulate cyclic
strain-induced ERK1/2 phosphorylation. A, ECs were
transfected with either sense, antisense, or scrambled (Sc)
oligonucleotides (2 µmol/liter) to PKC- or PKC- for 6 h.
Two days after transfection, ECs were subjected to cyclic strain for 5 min (S5'). B, ECs were similarly transfected with
sense or antisense oligonucleotides (2 µmol/liter) to PKC-
or PKC- or inhibition peptide to PKC- (5 µmol/liter, PKC- i)
for 6 h. Two days after transfection, ECs were subjected to cylic
strain for 3 h (S3h). Total cell lysate was collected
for Western analysis using an antibody to pERK1/2. Equal amounts of
protein applied to each lane are shown by the ERK for each lane.
Results are representative of three separate experiments.
|
|
Cyclic Strain-induced PKC Activation Increases Transcriptional
Activity of Elk1 and MCP-1--
When the Ras/Raf-1/ERK1/2 signaling
pathway is triggered, it leads to the activation of downstream
transcriptional factors including activator protein-1 and ternary
complex factors Elk1/TCF (ternary complex factors). Since PKC
isoforms contribute to strain-induced ERK1/2 activity and ERK1/2
activation increases the transcriptional activity of Elk1 by
phosphorylation, we thus investigated whether PKC isoforms elicit the
transcriptional activity of Elk1. To demonstrate Elk1 activity, plasmid
GAL4/Elk1-(307-428), which encodes the fusion protein of the
GAL4/DNA-binding domain fused to the activation domain of Elk1, was
cotransfected with GAL4-Luc, a chimeric construct consisting of five
copies of the GAL-4 binding sequences and the luciferase reporter, into
ECs. These ECs were then subjected to cyclic strain. When ECs were
transfected with the antisense to PKC- or PKC- , strain-induced
Elk1 transcriptional activities were significantly reduced to levels
close to that of static control ECs (Fig.
7A). In contrast, ECs
transfected with scramble oligonucleotides did not affect the Elk1
induction by cyclic strain. Similarly, ECs transfected with an
antisense to PKC- or PKC- attenuated MCP-1 promotor
activity (Fig. 7B). These results demonstrated that cyclic
strain to ECs increases ERK1/2 activity, which is subsequently followed
by an increase of transcriptional activity of Elk1. These results
further confirm the importance of PKC isoforms (- and - ) in
modulating the signaling pathway in ECs under cyclic strain.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 7.
Cyclic strain-induced PKC activation
increases transcriptional activity of Elk1 and MCP-1 in ECs. A,
plasmid GAL4/Elk1-(307-428) was cotransfected with GAL4-Luc into ECs.
These ECs were transiently transfected with the antisense to PKC- or
PKC- followed by cyclic strain for 6 h. ECs transfected with
scramble oligonucleotides (Sc) were used as control. *,
p < 0.05 versus strained ECs that have been
transfected with scramble oligonucleotides. B, ECs were
transiently transfected with MCP-1 promoter construct containing a
luciferase reporter gene. ECs were cotransfected with scramble
(Sc) or antisense to PKC- or PKC- and then subjected
to cyclic strain for 6 h. Luciferase activity was measured with
the cell extract. Results are shown as mean ± S.E. from three
separate experiments. *, p < 0.05 versus
strained ECs that have been transfected with corresponding scramble
oligonucleotides.
|
|
Taken together, our results clearly show that PKC isoforms are involved
in endothelial responses to cyclic strain. The PKC- appears
to play an important role for sustained Raf/ERK1/2 activation in ECs
constantly under hemodynamic influences. The activation of this PKC
isoform and the subsequent signaling pathway followed by gene
modulation are crucial for cellular adaptation to a hemodynamic environment.
 |
DISCUSSION |
Earlier studies indicated that PKC activities are increased in ECs
under shear or cyclic strain treatment (33). Our previous studies
showed that PKC is involved in cyclic strain-induced Et-1 and MCP-1
gene expression (10, 30). Cyclic strain to ECs results in a biphasic
increase in DAG (17) that corresponds to early transient PKC activity
followed by sustained elevated PKC activity (33). Although PKC
involvement in mechanical force-induced endothelial responses has been
acknowledged (33), studies have indicated only that specific isoforms
PKC- and PKC- are involved in shear-induced endothelial response
(21, 34). The mechanisms as to what and how PKC isoforms are involved
in cellular responses to mechanical forces remain unclear. The present
study shows that PKC- and PKC- are sequential activated and are
involved in cyclic strain-induced Raf/ERK1/2 activation. Several lines
of evidence support this notion. First, the transmigration of PKC-
and PKC- from the cytosolic to the membrane fraction was a
sequential event (i.e. PKC- was involved in an early
activation, whereas PKC- was activated at a late but sustained
phase). Second, ECs treated with a PKC inhibitor abolished the Raf-1
phosphorylation by cyclic strain. Third, a sequential association of
PKC- and PKC- with the signaling molecule Raf-1 was shown.
Fourth, a PKC inhibitor inhibited strain-induced ERK1/2 activation,
indicating a crucial role of PKC in the Raf/ERK1/2 signaling pathway.
Fifth, ECs treated with a Ca2+-dependent PKC
inhibitor (Go 6976) showed an inhibition in the early phase but not the
late sustained phase of ERK1/2 activation. Sixth, ECs transfected with
the antisense to PKC- inhibited only early and not late ERK1/2
activation, whereas the antisense or inhibitory peptide to PKC-
suppressed late, sustained ERK1/2 activation. Consistently, an
antisense to PKC- did not inhibit late ERK1/2 activation. All of
these data confirm that PKC- and PKC- are sequentially activated
and are required for Raf/ERK1/2 activity. Furthermore, ECs treated with
an antisense to each PKC isoform significantly reduced the
transcriptional activity of Elk1, a downstream substrate of ERK1/2. As
a result of decreasing ERK1/2 activity, antisense to each PKC isoform
also inhibited MCP-1 transcriptional activity. All of these results
indicate that the sequential activation of PKC- and PKC- is
essential for Raf/ERK1/2 activation in cyclic strain-treated ECs. The
activation of ERK1/2 and its downstream Elk-1 activation may result in
gene induction.
PKC- belongs to the family of conventional protein kinases that are
Ca2+-dependent, whereas PKC- is a novel
protein kinase. It is well recognized that when ECs are subjected to
hemodynamic forces, Ca2+ mobilization plays an essential
role in endothelial responses (20, 35). When ECs are under hemodynamic
treatment, a rapid increase of [Ca2+]i (35, 36),
inositol triphosphate and DAG (17) occurs. DAG is produced from
hydrolysis of PI and PC (17). DAG derived from PI after phospholipase C
activation is responsible for the translocation of PKC- (37). This
transient DAG release coupled with Ca2+ mobilization may
activate PKC- during the early response of ECs to cyclic strain. PC
hydrolysis, however, provides a sustained source of DAG in growth
factor-stimulated cells that is compatible with the signaling activity
required for long-term response (38). Although PKC- , - , - ,
- , and - have been identified in ECs (18, 21), only PKC- has
been implicated to be involved in shear-induced ERK1/2 activity (21).
In the present cyclic strain study, PKC- participated in early
ERK1/2 activity. Although signaling events by which each PKC isoform
activates ERK1/2 remain to be further characterized, PKC involvement in
Raf-1 activation and sequential association of PKC isoforms with Raf-1
indicate that PKC- and PKC- contribute to Raf-1/ERK1/2
activation. In addition, the fact that the antisense to each PKC
isoform temporally inhibits ERK1/2 activity also suggests that these
two PKC isoforms contribute to Raf-1 activation. PKC- has been
reported to phosphorylate and activate Raf-1 (31, 32, 39). PKC- can
be down-regulated by treating cells with phorbol ester. However, this
down-regulation does not inhibit Raf-1 activation stimulated by growth
factor (40). Interestingly, PKC- can be activated by PC-derived DAG (41). Activation of Raf-1 via PC hydrolysis and PKC- phosphorylation was previously indicated to play a role in maintaining sustained activity of Raf-1/MEK/ERK1/2 pathway (42). PKC- overexpression was
shown to induce a sustained phosphorylation of MAPK in epidermal growth
factor-treated PC12 cells (43). Another study suggested that PKC-
and PKC- enhance the signaling pathway Raf-1/MEK/ERK/TCF, which converges on the serum response element (24). Our previous study
demonstrated that the serum response element in the promoter region of
Egr-1 is involved in cyclic strain-induced Egr-1 expression (15). Based
on these previous observations and our current findings, it is strongly
suggested that both PKC- and PKC- were involved in Raf-1
activation and contributed to the prolonged ERK1/2 activation. Thus,
specific PKC isoforms are important in integrating networks of
signaling pathways that consequently modulate gene expression in ECs
under hemodynamic conditions.
The major finding of the present study is that sequential activation of
PKC- and PKC- is part of a mechano-sensitive signaling pathway
that leads to activation of ERK1/2 and gene induction. In addition to
sequential activation of PKC- and PKC- and their temporal
association with Raf-1, our antisense studies also showed that there is
sequential activation of PKC isoforms in cyclic strain-treated ECs. The
use of antisenses to PKC isoforms has an advantage over the use of PKC
inhibitors in terms of specificity (44, 45). Our findings demonstrate
the activation of PKC- at 5 min and a late activation of PKC- in
ECs under cyclic strain. These results are consistent with an earlier
report that PKC- is required for shear-induced ERK1/2 activity (21).
However, shear-induced ERK1/2 activity is transient and returns to
basal level by 60 min after shear treatment (21). The reason for this discrepancy remains unclear, and it could be due to the nature of the
forces studied. Steady laminar flow produces a constant shear stress to
ECs and does not produce macroscopic strain, whereas our strain system
offers cyclical changes of stretch to which ECs may be more sensitive.
A moderate but sustained PKC activation in cyclic strain-treated ECs
was previously reported (33). The present study shows that specific PKC
isoforms were involved. Although we cannot rule out the possibility
that other PKC isoforms may also contribute to ERK1/2 activation, our
results clearly show that PKC- and PKC- are sequentially
activated and contribute to ERK1/2 activation in ECs under cyclic strain.
Recent studies indicate that PKC activation can be modulated by
intracellular redox status. H2O2 treatment of
cells causes PKC activation, and H2O2-triggered
phosphorylation sites of PKC isoforms have been demonstrated (46). A
recent report of glutathione negatively regulating the activation of
cellular PKC isoforms further supports that intracellular redox
status affects PKC activation (47). We demonstrated that reactive
oxygen species, including H2O2, act as second
messengers that contribute to hemodynamic force-induced
Ras/Raf-1/ERK1/2 activation and gene expression (12, 13, 15).
Intracellular redox changes may modulate PKC activation in our cyclic
strain-treated ECs. Since our strain device produced nonhomogeneity of
force on the ECs, the possibility of PKC transmigration as the
subsequent effect of H2O2 produced during
cyclic strain could not be ruled out. Reactive oxygen species acts as a second messenger in growth factor-treated cells (48) and is
believed to play a role during hypertension-induced vascular injury
(49). PKC activation may be a ubiquitous response in ECs subjected to
growth factor and hemodynamic stimuli. Our finding of PKC-
involvement in strain-induced ERK1/2 is also consistent with a previous
report of PKC- requirement in mechano-sensitive ERK1/2 activation
(21).
The present study clearly demonstrates that PKC isozymes are essential
signaling molecules for transduction of cyclic strain. PKC- and
PKC- act as Raf-1 activators that lead to a prolonged effect on the
MAPK signaling pathway and gene induction. Recent studies indicate that
lack of fluid shear flow triggers apoptosis in ECs (50). The activation
of PKC isozymes by cyclic strain serves not only as a signaling
response but is also important for cellular growth and survival.
Elucidating the signaling mechanism mediated via PKC isozymes in ECs
during hemodynamic changes is key for further understanding of
endothelial dysfunction during atherosclerosis, hypertension,
and reperfusion-induced vascular injuries.
 |
FOOTNOTES |
*
This work was supported in part by National Science Council
(Taiwan, ROC) Grant NSC 86-2314-B001-004-M26.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Cardiovascular
Division, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, ROC 11529. Tel.: 886-2-26523907; Fax: 886-2-27899143; E-mail:
lingwang@ibms.sinica.edu.tw.
Published, JBC Papers in Press, June 8, 2001, DOI 10.1074/jbc.M011317200
 |
ABBREVIATIONS |
The abbreviations used are:
EC, endothelial
cell;
PKC, protein kinase C;
ERK, extracellular signal-regulated
protein kinase;
pERK, phosphorylated ERK;
MCP-1, monocyte chemotactic
protein-1;
DAG, diacylglycerol;
PI, phosphatidylinositide;
PC, phosphatidylcholine;
MAPK, mitogen-activated protein kinase;
Et-1, endothelin-1;
Egr-1, early growth response-1;
ICAM, intercellular
adhesion molecule;
PAGE, polyacrylamide gel electrophoresis;
MEK, mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase.
 |
REFERENCES |
| 1.
|
Chien, S.,
Li, S.,
and Shyy, Y. J.
(1998)
Hypertension
31,
162-169
|
| 2.
|
Sadoshima, J.,
and Izumo, S.
(1993)
EBMO J.
12,
1681-1692
|
| 3.
|
Takahashi, M.,
and Berk, B. C.
(1996)
J. Clin. Invest.
98,
2623-2631
|
| 4.
|
Zou, Y.,
Hu, Y.,
Metzler, B.,
and Xu, Q.
(1998)
Int. J. Mol. Med.
1,
827-834
|
| 5.
|
Bao, X.,
Lu, C.,
and Frangos, J. A.
(1999)
Arterioscler. Thromb. Vasc. Biol.
19,
996-1003
|
| 6.
|
Schwatchtgen, J. L.,
Houston, P.,
Campbell, C.,
Sukhatme, V.,
and Braddock, M.
(1998)
J. Clin. Invest.
101,
2540-2549
|
| 7.
|
Jalali, S.,
Li, Y. S.,
Sotoudeh, M.,
Yuan, S.,
Li, S.,
Chien, S.,
and Shyy, Y. J.
(1998)
Arterioscler. Thromb. Vasc. Biol.
18,
227-234
|
| 8.
|
Ito, W. D.,
Arras, M.,
Winkler, B.,
Scholz, D.,
Schaper, J.,
and Schaper, W.
(1997)
Circ. Res.
80,
829-837
|
| 9.
|
Chiu, J. J.,
Wung, B. S.,
Shyy, Y. J.,
Hsieh, S. J.,
and Wang, D. L.
(1997)
Arterioscler. Thromb. Vasc. Biol.
17,
3570-3577
|
| 10.
|
Wang, D. L.,
Wung, B. S.,
Shyy, Y. J.,
Lin, C. F.,
Chao, Y. J.,
Usami, S.,
and Chien, S.
(1995)
Circ. Res.
77,
294-302
|
| 11.
|
Wung, B. S.,
Cheng, J. J.,
Chao, Y. J.,
Lin, J.,
Shyy, Y. J.,
and Wang, D. L.
(1996)
Am. J. Physiol.
270,
H1462-H1468
|
| 12.
|
Wung, B. S.,
Cheng, J. J.,
Hsieh, H. J.,
Shyy, Y. J.,
and Wang, D. L.
(1997)
Circ. Res.
81,
1-7
|
| 13.
|
Cheng, J. J.,
Wung, B. S.,
Chao, Y. J.,
and Wang, D. L.
(1998)
Hypertension
31,
125-130
|
| 14.
|
Cheng, J. J.,
Wung, B. S.,
Chao, Y. J.,
and Wang, D. L.
(1996)
Hypertension
28,
386-391
|
| 15.
|
Wung, B. S.,
Cheng, J. J.,
and Wang, D. L.
(1999)
Circ. Res.
84,
804-812
|
| 16.
|
Liang, F.,
Lu, S.,
and Gardner, D. G.
(2000)
Hypertension
35,
188-192
|
| 17.
|
Evans, L.,
Frenkel, L.,
Brophy, C. M.,
Rosales, O.,
Sai Sudhaker, C. B.,
Li, G.,
Du, W.,
and Sumpio, B. E.
(1997)
J. Physiol.
272,
C650-C656
|
| 18.
|
Haller, Z.,
Ziegler, W.,
Lindschau, C.,
and Luft, F. C.
(1996)
Arterioscler. Thromb. Vasc. Biol.
16,
678-686
|
| 19.
|
Morita, T.,
Kurihara, H.,
Maemura, K.,
Yoshizumi, M.,
Nagai, R.,
and Yazaki, Y.
(1994)
Circ. Res.
75,
630-636
|
| 20.
|
Morawietz, H.,
Talanow, R.,
Szibor, M.,
Rueckschloss, U.,
Schubert, A.,
Bartling, B.,
Darmer, D.,
and Holtz, J.
(2000)
J. Physiol.
525,
761-770
|
| 21.
|
Traub, O.,
Monia, B. P.,
Dean, N. M.,
and Berk, B. C.
(1997)
J. Biol. Chem.
272,
31251-31257
|
| 22.
|
Mills, I.,
Cohen, C. R.,
Kamal, K.,
Li, G.,
Shin, T.,
Du, W.,
and Sumpio, B. E.
(1997)
J. Cell. Physiol.
170,
228-234
|
| 23.
|
Liao, D. F.,
Monia, B.,
Dean, N.,
and Berk, B. C.
(1997)
J. Biol. Chem.
272,
6146-6150
|
| 24.
| Soh, J. W., Lee, E. H., Prywes, E., and Weinstein, I. B. (1999) 19, 1313-1324
|
| 25.
|
Gilbert, J. A.,
Weinhold, P. S.,
Banes, A. J.,
Link, G. W.,
and Jones, G. L.
(1994)
J. Biomech.
27,
1169-1177
|
| 26.
|
Shyy, Y. J.,
Lin, M. C.,
Lu, Y.,
Petrime, M.,
and Chien, S.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8069-8073
|
| 27.
|
Xia, P.,
Aiello, L. P.,
Ishii, H.,
Jiang, Z. Y.,
Park, D. J.,
Robinson, G. S.,
Takagi, H.,
Newsome, W. P.,
Jirousek, M. R.,
and King, G. L.
(1996)
J. Clin. Invest.
98,
2018-2026
|
| 28.
|
Hempel, A.,
Maasch, C.,
Heintze, U.,
Lindschau, C.,
Dietz, R.,
Luft, F. C.,
and Haller, H.
(1997)
Circ. Res.
81,
363-371
|
| 29.
|
Yedovitzky, M.,
Mochly, R. D.,
Johnson, J. A.,
Gray, M. O.,
Ron, D.,
Abramovitch, E.,
Cerasi, E.,
and Nesher, R.
(1997)
J. Biol. Chem.
272,
1417-1420
|
| 30.
|
Wang, D. L.,
Wung, B. S.,
Peng, Y. C.,
and Wang, J. J.
(1995)
J. Cell. Physiol.
163,
400-406
|
| 31.
|
Kolch, W.,
Heidecker, G.,
Kochs, G.,
Hummel, R.,
Vahidi, H.,
Mischak, H.,
Finkenzeller, G.,
Marme, D.,
and Rapp, U. R.
(1993)
Nature
364,
249-252
|
| 32.
|
Sajan, M. P.,
Standaert, M. L.,
Bandyopadhyay, G.,
Quon, M. J.,
Burke, T. R.,
and Farese, R. V., Jr.
(1999)
J. Biol. Chem.
274,
30495-30500
|
| 33.
|
Takei, T.,
Han, O.,
Ikeda, M.,
Male, P.,
Mills, I.,
and Sumpio, B. E.
(1997)
J. Cell. Biochem.
67,
327-337
|
| 34.
|
Hu, Y. L.,
and Chien, S.
(1997)
J. Histochem. Cytochem.
45,
237-249
|
| 35.
|
Berk, B. C.,
Corson, M. A.,
Peterson, T. E.,
and Tseng, H.
(1995)
J. Biomech.
28,
1439-1450
|
| 36.
|
Rosales, O. R.,
Isales, C. M.,
Barrett, P. Q.,
Brophy, C.,
and Sumpio, S. E.
(1997)
Biochem. J.
326,
385-392
|
| 37.
|
Neri, L. M.,
Borgatti, P.,
Capitani, S.,
and Martelli, A. M.
(1998)
J. Biol. Chem.
273,
29738-29744
|
| 38.
|
Nishizuka, Y.
(1992)
Science
(1992), 258,
607-614
|
| 39.
|
Marais, R.,
Light, Y.,
Mason, C.,
Paterson, H.,
Olson, M. F.,
and Marshall, C. J.
(1998)
Science
280,
109-112
|
| 40.
|
App, H.,
Hazan, R.,
Zillberstein, A.,
Ullrich, A.,
Schlessinger, J.,
and Rapp, U. R.
(1991)
Mol. Cell. Biol.
11,
913-919
|
| 41.
|
Ha, K. S.,
and Exton, J. H.
(1993)
J. Biol. Chem.
268,
10534-10539
|
| 42.
|
Cai, H.,
Smola, U.,
Wixler, V.,
Eisenmann-Tappe, I.,
Diaz-Meco, M. T.,
Moscat, J.,
Rapp, U.,
and Cooper, G. M.
(1997)
Mol. Cell. Biol.
17,
732-741
|
| 43.
|
Brodie, C.,
Bogi, K.,
Lazarovici, P.,
Petrovics, G.,
Anderson, W. B.,
and Blumberg, P. M.
(1999)
Cell Growth Differ.
10,
183-191
|
| 44.
|
Ueffing, M.,
Lovric, J.,
Philipp, A.,
Mischak, H.,
and Kolch, W.
(1997)
Oncogene
15,
2971-2977
|
| 45.
|
Dean, N. M.,
and Mckay, R.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
11762-11766
|
| 46.
|
Konishi, H.,
Tanaka, Y.,
Matsuzaki, H,.,
Ono, Y.,
Kikkawa, U.,
and Nishizuka, Y.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11233-11237
|
| 47.
|
Ward, N. E.,
Pierce, D. S.,
Chung, S. E.,
Gravitt, K. R.,
and O'Brian, C. A.
(1998)
J. Biol. Chem.
273,
12558-12566
|
| 48.
|
Sattler, M.,
Winkler, T.,
Verma, S.,
Byrne, C. H.,
Shrikhande, G.,
Salgia, R.,
and Griffin, J. D.
(1999)
Blood
93,
2928-2935
|
| 49.
|
Berk, B. C.
(1999)
Thromb. Haemost.
82,
810-817
|
| 50.
|
Traub, O.,
and Berk, B. C.
(1998)
Arterioscler. Thromb. Vasc. Biol.
18,
677-685
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. K. Linnemann and S. A. Krawetz
Silencing by nuclear matrix attachment distinguishes cell-type specificity: association with increased proliferation capacity
Nucleic Acids Res.,
May 1, 2009;
37(9):
2779 - 2788.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Koh, R. D. Mahan, and G. E. Davis
Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling
J. Cell Sci.,
April 1, 2008;
121(7):
989 - 1001.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Huang, H.-C. Cheng, R. Isom, C.-S. Chen, R. A. Levine, and B. U. Pauli
Protein Kinase C{epsilon} Mediates Polymeric Fibronectin Assembly on the Surface of Blood-borne Rat Breast Cancer Cells to Promote Pulmonary Metastasis
J. Biol. Chem.,
March 21, 2008;
283(12):
7616 - 7627.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Shi, Y.-J. Chiu, Y. Cho, T. A. Bullard, M. Sokabe, and K. Fujiwara
Down-regulation of ERK but not MEK phosphorylation in cultured endothelial cells by repeated changes in cyclic stretch
Cardiovasc Res,
March 1, 2007;
73(4):
813 - 822.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, J. M. Urban, M. L. Cayer, H. K. Plummer III, and C. A. Heckman
Actin-based features negatively regulated by protein kinase C-{epsilon}
Am J Physiol Cell Physiol,
November 1, 2006;
291(5):
C1002 - C1013.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. H. Ali, P. T. Mungai, and P. T. Schumacker
Stretch-induced phosphorylation of focal adhesion kinase in endothelial cells: role of mitochondrial oxidants
Am J Physiol Lung Cell Mol Physiol,
July 1, 2006;
291(1):
L38 - L45.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Song and L. K. Kaczmarek
Modulation of Kv3.1b Potassium Channel Phosphorylation in Auditory Neurons by Conventional and Novel Protein Kinase C Isozymes
J. Biol. Chem.,
June 2, 2006;
281(22):
15582 - 15591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Celil and P. G. Campbell
BMP-2 and Insulin-like Growth Factor-I Mediate Osterix (Osx) Expression in Human Mesenchymal Stem Cells via the MAPK and Protein Kinase D Signaling Pathways
J. Biol. Chem.,
September 9, 2005;
280(36):
31353 - 31359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Ridge, L. Linz, F. W. Flitney, E. R. Kuczmarski, Y.-H. Chou, M. B. Omary, J. I. Sznajder, and R. D. Goldman
Keratin 8 Phosphorylation by Protein Kinase C {delta} Regulates Shear Stress-mediated Disassembly of Keratin Intermediate Filaments in Alveolar Epithelial Cells
J. Biol. Chem.,
August 26, 2005;
280(34):
30400 - 30405.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Fu, A. P. Naren, X. Gao, G. U. Ahmmed, and A. B. Malik
Protease-activated Receptor-1 Activation of Endothelial Cells Induces Protein Kinase C{alpha}-dependent Phosphorylation of Syntaxin 4 and Munc18c: ROLE IN SIGNALING P-SELECTIN EXPRESSION
J. Biol. Chem.,
February 4, 2005;
280(5):
3178 - 3184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-H. Lee, M. J. Son, S.-H. Oh, S.-B. Rho, K. Park, Y.-J. Kim, M.-S. Park, and J.-H. Lee
Thymosin {beta}10 Inhibits Angiogenesis and Tumor Growth by Interfering with Ras Function
Cancer Res.,
January 1, 2005;
65(1):
137 - 148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Mason, R. Steinberg, E. A. Lidington, A. R. Kinderlerer, M. Ohba, and D. O. Haskard
Decay-accelerating Factor Induction on Vascular Endothelium by Vascular Endothelial Growth Factor (VEGF) Is Mediated via a VEGF Receptor-2 (VEGF-R2)- and Protein Kinase C-{alpha}/{epsilon} (PKC{alpha}/{epsilon})-dependent Cytoprotective Signaling Pathway and Is Inhibited by Cyclosporin A
J. Biol. Chem.,
October 1, 2004;
279(40):
41611 - 41618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zagar, G. Chaumaz, and M. Lieberherr
Signaling Cross-talk from G{beta}4 Subunit to Elk-1 in the Rapid Action of Androgens
J. Biol. Chem.,
January 23, 2004;
279(4):
2403 - 2413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Illario, A. L. Cavallo, K. U. Bayer, T. Di Matola, G. Fenzi, G. Rossi, and M. Vitale
Calcium/Calmodulin-dependent Protein Kinase II Binds to Raf-1 and Modulates Integrin-stimulated ERK Activation
J. Biol. Chem.,
November 14, 2003;
278(46):
45101 - 45108.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. T. Budnik, B. Brunswig-Spickenheier, and A. K. Mukhopadhyay
Lysophosphatidic Acid Signals through Mitogen-Activated Protein Kinase-Extracellular Signal Regulated Kinase in Ovarian Theca Cells Expressing the LPA1/edg2-Receptor: Involvement of a Nonclassical Pathway?
Mol. Endocrinol.,
August 1, 2003;
17(8):
1593 - 1606.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Y. Su, K. M. Reber, C. A. Nankervis, and P. T. Nowicki
Development of the myogenic response in postnatal intestine: role of PKC
Am J Physiol Gastrointest Liver Physiol,
March 1, 2003;
284(3):
G445 - G452.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-J. Cheng, Y.-J. Chao, and D. L. Wang
Cyclic Strain Activates Redox-sensitive Proline-rich Tyrosine Kinase 2 (PYK2) in Endothelial Cells
J. Biol. Chem.,
December 6, 2002;
277(50):
48152 - 48157.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Lavelin, N. Meiri, M. Einat, O. Genina, and M. Pines
Mechanical strain regulation of the chicken glypican-4 gene expression in the avian eggshell gland
Am J Physiol Regulatory Integrative Comp Physiol,
October 1, 2002;
283(4):
R853 - R861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Paruchuri, B. Hallberg, M. Juhas, C. Larsson, and A. Sjolander
Leukotriene D4 activates MAPK through a Ras-independent but PKC{epsilon}-dependent pathway in intestinal epithelial cells
J. Cell Sci.,
January 5, 2002;
115(9):
1883 - 1893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Xiao and L. Zhang
ERK MAP kinases regulate smooth muscle contraction in ovine uterine artery: effect of pregnancy
Am J Physiol Heart Circ Physiol,
January 1, 2002;
282(1):
H292 - H300.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|